AstraZeneca's Breast Cancer Drug Fails Key Trial, Narrowing Treatment Options

By Editor • September 12, 2026 • 1 min read

AstraZeneca announced on Friday that its breast cancer medication, camizestrant, did not achieve success in a critical clinical trial that tested its effectiveness as a first-line treatment for advanced tumors. This outcome poses a significant challenge for the future use of the drug.

The pivotal SERENA-4 trial involved patients suffering from ER-positive, HER2-negative advanced breast cancer who had not yet received systemic therapy for their condition. The results revealed that camizestrant, when paired with another medication, did not perform better than the standard treatment in delaying cancer progression.

This setback comes shortly after camizestrant received accelerated approval in the United States under the name Etcamah, specifically for patients exhibiting mutations in their tumors that indicate a developing resistance to treatment. Had the SERENA-4 trial yielded positive results, it could have significantly expanded the drug's market potential.

Source: www.statnews.com

KFF Health News Journalists Spotlight Critical Health Issues on National Platforms

By Editor • September 12, 2026 • 1 min read

KFF Health News journalists discuss critical health issues, including opioid settlements, primary care shortages, and gun violence's impact on children.

Health

Scholar Rock Secures FDA Approval for Groundbreaking SMA Therapy

By Editor • September 11, 2026 • 1 min read

Scholar Rock's Isembyld receives FDA approval as the first therapy targeting muscle loss in spinal muscular atrophy, promising improved patient mobility.